Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 8: 987 - 998

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.08.001

Innovative research team achievement column

Invitro screening and validation of novel targeted therapeutic strategy against diffuse intrinsic pontine glioma

  • Rui LI ,
  • Yu-jie HAN ,
  • Lei ZHANG ,
  • Yu-jie TANG
Expand
  • Key Laboratory of Cell Differentiation and Apoptosis of Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China
TANG Yu-jie, E-mail: yujietang@shsmu.edu.cn.

Online published: 2021-08-13

Supported by

National Natural Science Foundation of China(81772655);Innovative Research Team of High-Level Local Universities in Shanghai(SSMU-ZDCX20180800)

Fold

Abstract

Objective

·To find and identify new targeted therapeutic compounds and combinations for diffuse intrinsic pontine glioma (DIPG) from the perspective of epigenetics.

Methods

·Selection of small molecule compounds was based on the previously published transcriptome analysis of 8 cases of DIPG and 6 cases of normal brain tissues. New inhibitory compounds of DIPG were identified by single agent screening in DIPG primary tumor cells. The changes of target genes at mRNA and protein expression level were detected by real-time PCR and Western blotting after drug treatment. The effects of drug treatment on the proliferation and apoptosis of DIPG primary tumor cells were detected by FACS analyses after EdU and Annexin V/propidium iodide staining, respectively. The combinatory screening of small molecular compounds was performed with bromodomain and extra terminal protein (BET) inhibitor JQ1 or histone deacetylase (HDAC) inhibitor panobinostat, and the drug combination with inhibitory effect on DIPG was verified in vitro.

Results

·Sixty-six small molecules were chosen to be applied to screening. Single agent screening identified that YM155 could significantly inhibit DIPG primary tumor cell growth, and BIRC5 (baculoviral IAP repeat containing 5; gene encoding survivin), a target gene of YM155, was significantly upregulated in DIPG tumor tissues (P=0.018). YM155 could reduce the expression of BICR5 at both mRNA and protein levels. YM155 could repress proliferation and induce apoptosis of DIPG. CX4945 and ABT-737 from the targeted small molecular library were combined with JQ1 (BET inhibitor) and panobinostat (HDAC inhibitor), respectively,which could synergistically inhibit the activity of DIPG cells in vitro.

Conclusion

·Novel targeted therapeutic strategies for DIPG has been identified through single drug and combination drug screening, providing basis for furthervalidation in vivo and therapeutic mechanism exploration.

Key words： diffuse intrinsic pontine glioma (DIPG); single targeted small molecule compounds screening; YM155; baculoviral IAP repeat containing 5 (BIRC5); drug combinatory screening

Cite this article

Rui LI , Yu-jie HAN , Lei ZHANG , Yu-jie TANG . Invitro screening and validation of novel targeted therapeutic strategy against diffuse intrinsic pontine glioma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(8) : 987 -998 . DOI: 10.3969/j.issn.1674-8115.2021.08.001

References

1 Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
2 Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012—2016[J]. Neuro Oncol, 2019, 21(): v1-v100.
3 Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and European society for pediatric oncology DIPG registries[J]. J Clin Oncol, 2018, 36(19): 1963-1972.
4 Aziz-Bose R, Monje M. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets[J]. Curr Opin Oncol, 2019, 31(6): 522-530.
5 Zhang X, Zhang Z. Oncohistone mutations in diffuse intrinsic pontine glioma[J]. Trends Cancer, 2019, 5(12): 799-808.
6 Warren KE. Diffuse intrinsic pontine glioma: poised for progress[J]. Front Oncol, 2012, 2: 205.
7 Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life[J]. Nature, 2011, 469(7330): 343-349.
8 Nagaraja S, Vitanza NA, Woo PJ, et al. Transcriptional dependencies in diffuse intrinsic pontine glioma[J]. Cancer Cell, 2017, 31(5): 635-652.e6.
9 Grasso C, Tang Y, Truffaux N, et al. Functionally-defined therapeutic targets in diffuse intrinsic pontine glioma[J]. Nat Med, 2015, 21(6): 555-559.
10 Borrelli EP, McGladrigan CG. Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials[J]. J Oncol Pharm Pract, 2020: 1078155220941937.
11 Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: the example of lymphomas[J]. Pharmacol Ther, 2020, 215: 107631.
12 Altieri DC. Survivin, cancer networks and pathway-directed drug discovery[J]. Nat Rev Cancer, 2008, 8(1): 61-70.
13 Kim YH, Kim SM, Kim YK, et al. Evaluation of survivin as a prognostic marker in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2010, 39(5): 368-375.
14 Kelly RJ, Thomas A, Rajan A, et al. A phase Ⅰ/Ⅱ study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer[J]. Ann Oncol, 2013, 24(10): 2601-2606.
15 Tolcher AW, Quinn DI, Ferrari A, et al. A phase Ⅱ study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer[J]. Ann Oncol, 2012, 23(4): 968-973.
16 Dahl NA, Danis E, Balakrishnan I, et al. Super elongation complex as a targetable dependency in diffuse midline glioma[J]. Cell Rep, 2020, 31(1): 107485.
17 Chou TC. The combination index (CI<1) as the definition of synergism and of synergy claims[J]. Synergy, 2018, 7: 49-50.
19 Lin GL, Wilson KM, Ceribelli M, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening[J]. Sci Transl Med, 2019, 11(519): eaaw0064.
18 Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor[J]. Cancer Res, 2008, 68(9): 3421-3428.
20 Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy[J]. Cancer Res, 2010, 70(24): 10288-10298.
21 Eke I, Cordes N. Focal adhesion signaling and therapy resistance in cancer[J]. Semin Cancer Biol, 2015, 31: 65-75.
22 Schramm K, Iskar M, Statz B, et al. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas[J]. Neuro Oncol, 2019, 21(7): 867-877.
23 Fortin J, Tian RX, Zarrabi I, et al. Mutant ACVR1 arrests glial cell differentiation to drive tumorigenesis in pediatric gliomas[J]. Cancer Cell, 2020, 37(3): 308-323.e12.
24 Koncar RF, Dey BR, Stanton AJ, et al. Identification of novel RAS signaling therapeutic vulnerabilities in diffuse intrinsic pontine gliomas[J]. Cancer Res, 2019, 79(16): 4026-4041.
25 Larson JD, Kasper LH, Paugh BS, et al. Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression[J]. Cancer Cell, 2019, 35(1): 140-155.e7.
26 Batool S, Raza H, Zaidi J, et al. Synapse formation: from cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders[J]. J Neurophysiol, 2019, 121(4): 1381-1397.
27 Friedmann-Morvinski D, Bushong EA, Ke E, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice[J]. Science, 2012, 338(6110): 1080-1084.
28 Filbin MG, Tirosh I, Hovestadt V, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq[J]. Science, 2018, 360(6386): 331-335.
29 Iwagawa T, Watanabe S. Molecular mechanisms of H3K27me3 and H3K4me3 in retinal development[J]. Neurosci Res, 2019, 138: 43-48.
30 Deaton AM, Bird A. CpG islands and the regulation of transcription[J]. Genes Dev, 2011, 25(10): 1010-1022.
31 Lin GL, Wilson KM, Ceribelli M, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening[J]. Sci Transl Med, 2019, 11(519): eaaw0064.
32 van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment[J]. Drug Resist Updat, 2015, 19: 1-12.
33 Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases[J]. Nat Rev Cancer, 2020, 20(1): 26-41.
34 Minematsu T, Sonoda T, Hashimoto T, et al. Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats[J]. Biopharm Drug Dispos, 2012, 33(3): 160-169.
35 Cheng ZX, Gong YY, Ma YF, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma[J]. Clin Cancer Res, 2013, 19(7): 1748-1759.
36 Matzuk MM, McKeown MR, Filippakopoulos P, et al. Small-molecule inhibition of BRDT for male contraception[J]. Cell, 2012, 150(4): 673-684.
37 Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors[J]. Biomaterials, 2009, 30(12): 2302-2318.
38 Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma[J]. Neuro Oncol, 2015, 17(): ii3-ii8.
39 Souweidane MM, Kramer K, Pandit-Taskar N, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial[J]. Lancet Oncol, 2018, 19(8): 1040-1050.
40 Luther N, Zhou ZP, Zanzonico P, et al. The potential of theragnostic 12?I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma[J]. Neuro Oncol, 2014, 16(6): 800-806.
Options
Outlines

/

〈 〉